Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VLA1553 in Healthy Volunteers
NCT03382964Phase 1Completed
- Sponsor
- Valneva
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fezolinetant in chikungunya virus infection (3 arms), sponsored by Valneva. Primary endpoints: Frequency of solicited injection site reactions at Day 14 and Frequency of solicited systemic reactions at Day 14. Started Mar 2018; status: completed.
02
Drugs
fezolinetant
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT03382964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382964.